Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Accumulated Depreciation (2016 - 2025)

Celldex Therapeutics (CLDX) has 7 years of Accumulated Depreciation data on record, last reported at $21.1 million in Q4 2021.

  • For Q4 2021, Accumulated Depreciation changed N/A year-over-year to $21.1 million; the TTM value through Dec 2021 reached $21.1 million, changed N/A, while the annual FY2021 figure was $21.1 million, N/A changed from the prior year.
  • Accumulated Depreciation reached $21.1 million in Q4 2021 per CLDX's latest filing, down from $28.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $28.4 million in Q4 2019 and bottomed at $21.1 million in Q4 2021.
  • Average Accumulated Depreciation over 4 years is $24.8 million, with a median of $24.9 million recorded in 2017.
  • Peak YoY movement for Accumulated Depreciation: rose 18.26% in 2017, then rose 8.47% in 2019.
  • A 4-year view of Accumulated Depreciation shows it stood at $23.6 million in 2017, then grew by 10.89% to $26.2 million in 2018, then grew by 8.47% to $28.4 million in 2019, then dropped by 25.62% to $21.1 million in 2021.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $21.1 million in Q4 2021, $28.4 million in Q4 2019, and $26.2 million in Q4 2018.